Destiny Pharma Ltd

Activities: Ingredients Research & Development

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to...
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards...
  3. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human...
  4. Mastering modified-release performance: excipient considerations Imagine a world where enhanced therapeutic efficacy, improved patient compliance and reduced adverse effects are tangible outcomes — even for drugs with short pharmacokinetic...
  5. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Drug Delivery

Positive update on the development of new XF‐platform drug formulations

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections
Research & Development

Destiny Pharma secures £1.6 million grant to fight microbial resistance

The UK-China antimicrobial resistance programme has allocated grant to research its novel XF drugs
Recruitment

Nick Rodgers joins Destiny Pharma
Research & Development

Destiny Pharma announces research collaboration with Aston University

Partnership will see a dedicated team investigate potential antimicrobial candidates against biofilms
Media

Destiny Pharma establishes Scientific Advisory Board

Pharmaceutical

Destiny Pharma appoints Neil Clark new CEO

Bill Love, Destiny’s founder, to become Chief Scientific Officer
Ingredients

Destiny Pharma receives US FDA QIDP designation for novel antibacterial product

Lead drug product in development for the prevention of post-surgical Staphyloccocal infections
Subscribe now